Search results

592 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
In development Remove In development filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Public health guidelines Remove Public health guidelines filter

Venous thromboembolism (prevention) - rivaroxaban [ID463]

In development [GID-TAG427] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]

In development [GID-TAG337] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Heart failure (acute) - serelaxin [ID673]

In development [GID-TAG454] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

In development [GID-TAG332] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Macular oedema (diabetic) - pegaptanib sodium [ID452]

In development [GID-TAG280] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]

In development [GID-TAG528] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Juvenile idiopathic arthritis - abatacept [ID27]

In development [GID-TAG402] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

In development [GID-TAG360] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

In development [GID-TAG424] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma - bortezomib (consolidation therapy) [ID529]

In development [GID-TAG320] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

In development [GID-TAG435] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Generalised anxiety disorder - quetiapine [ID347]

In development [GID-TAG421] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung transplantation with ex-vivo perfusion

In development [GID-IP1046] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

In development [GID-TA10324] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

In development [GID-TA10576] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

In development [GID-TA10391] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

In development [GID-TA10518] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]

In development [GID-TA10352] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]

In development [GID-TA10222] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]

In development [GID-TA10656] Expected publication date: 02 March 2022

Type

Technology appraisal guidance

Status

In development
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

In development [GID-TA10591] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atrial fibrillation - vernakalant [ID454]

In development [GID-TAG428] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair

In development [GID-IPG10191] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Superfcial vein arterialisation and selective venous embolisation for critical limb ischaemia

In development [GID-IPG10192] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Percutaneous endovascular forearm-arteriovenous fistula creation for haemodialysis access

In development [GID-IPG10193] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Tunnelled peritoneal drainage catheter insertion for treatment-resistant, recurrent ascites due to cirrhosis

In development [GID-IPG10194] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Regional nerve graft to restore corneal sensation

In development [GID-IPG10195] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Supercapsular Percutaneously Assisted Total Hip replacement for osteoarthritis

In development [GID-IPG10196] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Insertion of aortic arch remodelling graft as an adjunct to surgical repair of acute aortic dissection

In development [GID-IPG10197] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Percutaneous thoracic duct embolization for chyle leak

In development [GID-IPG10201] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Focal articular prosthetic resurfacing for treating articular cartilage defects in the knee

In development [GID-IPG10202] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Transcatheter tricuspid valve reconstruction for tricuspid regurgitation

In development [GID-IPG10198] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Sternoclavicular joint replacement for arthritis

In development [GID-IPG10199] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
External electrical muscle stimulation for urinary incontinence

In development [GID-IPG10200] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]

In development [GID-TA10759] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]

In development [GID-TA10588] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

In development [GID-TA10539] Expected publication date: 15 December 2021

Type

Technology appraisal guidance

Status

In development
Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids

In development [GID-IPG10147] Expected publication date: 31 March 2021

Type

Interventional procedures guidance

Status

In development
Extracorporeal whole liver perfusion for acute liver failure

In development [GID-IPG10164] Expected publication date: 31 March 2021

Type

Interventional procedures guidance

Status

In development
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

In development [GID-TA10566] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]

In development [GID-TA10398] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

In development [GID-TA10633] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development